Corynebacterium minutissimum

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Corynebacterium minutissimum is a Gram-positive, non-spore-forming, facultatively anaerobic, non-motile, short rod-shaped bacterium. It has been detected in at least 2 gut microbiome compilation studies or metastudies. The DNA G+C content is 58%. Corynebacterium minutissimum is probably a rare gut coloniser. (Yassin2002; Bernard2012Bergey)



  • This organism has been recovered from human faeces and clinical sources (blood, urine, vagina - CCUG). The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. It is an opportunistic pathogen. Is a known gut commensal.
    • GENERAL CHARACTERISTICS (Yassin2002); (Bernard2012Bergey);
    Character Response
  • Substrates hydrolysed or digested:
  • tyrosine;
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; glucose; maltose; sucrose; N-Ac glucosamine;
  • Active enzymes:
  • alkaline phosphatase; catalase;
    • SPECIAL FEATURES (Yassin2002);
    Character Response
  • ✗
  • Metabolites not produced:
  • H₂S; indole;
  • ✓
  • VP test:
  • active
  • ✗
  • Haemolysis:
  • absent
  • ✗
  • Nitrate:
  • not reduced
  • ✗
  • Pigments:
  • not produced
    • RESPONSE TO ANTIBIOTICS (Goldstein2003); (Tyrrell2012); (Goldstein2008); (Goldstein2000);
    Class Active Resistant
  • Penicillins:
  • ampicillin; imipenem; penicillin G;
  • ampicillin-sulbactam;
  • Macrolides:
  • erythromycin; quinupristin-dalfopristin; telithromycin;
  • josamycin;
  • Tetracyclines:
  • doxycycline; minocycline; tetracycline;
  • Quinolines:
  • levofloxacin; moxifloxacin;
  • Vancomycins:
  • vancomycin; teicoplanin;
  • Miscellaneous antibiotics:
  • daptomycin; linezolid; telithromycin;
  • clindamycin;

  • Lagier, J.-C., Armougom, F., Million, M., Hugon, P., Pagnier, I., Robert, C., Bittar, F., Fournous, G., Gimenez, G., Maraninchi, M., Trape, J.-F., Koonin, E. V., La Scola, B., & Raoult, D. (2012). Microbial culturomics: paradigm shift in the human gut microbiome study. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 18(12), 1185–1193.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Actinobacteria Class:  Actinomycetia Order:  Corynebacteriales Family:  Corynebacteriaceae Genus:  Corynebacterium Gram stain:  + O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  Sessile Morphology:  Short Rod Pigment:  neg
    Health:  Unknown
    Source:  human faeces and clinical sources (blood, urine, vagina - CCUG)
    DNA G+C(%):  58
    		Aesculin:  neg Urea:  neg Gelatin:  neg Casein:  neg Tyrosine:  + Hippurate:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg Fructose:  + Glucose:  + Mannose:  neg Rhamnose:  neg Ribose:  neg Xylose:  neg Cellubiose:  neg Lactose:  neg Maltose:  + Melezitose:  neg Sucrose:  + Trehalose:  neg Turanose:  neg Amygdalin:  neg Glycogen:  neg Inulin:  neg Starch:  neg Adonitol:  neg Glycerol:  neg Inositol:  neg Mannitol:  neg Sorbitol:  neg NAc-α-GA:  + Salicin:  neg
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Melibiose:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  + Urease:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  neg β-Glucosidase:  neg β-Glucuronidase:  neg α-Mannosidase:  neg ArgDH:  neg Chymotrypsin:  neg γ-Glu transf.:  neg LysDC:  neg OrnDC:  neg Trypsin:  neg CystineAA:  neg LeuAA:  vr PyrrolidAA:  neg ValAA:  neg AlkalineP:  + AcidP:  neg Esterase(C4):  neg EstLip(C8):  neg Lipase(C14):  neg Phosphoamidase:  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		H2S:  neg Indole:  neg Pigment:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    ampicillin:  S(MIC50): 0.5, MIC90: 4, RNG: (0.03-64)
    amp-sulb:  R(MIC50): >64, MIC90: >64, RNG: (1–>64)
    penicillin_G:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.12-32)
    piper-taz:  Var(MIC50): 0.25, MIC90: 16, RNG: (0.02-16)
    doripenem:  Var(MIC50): 1, MIC90: 8, RNG: (0.25–>32)
    ertapenem:  Var(MIC50): 1, MIC90: 32, RNG: (0.5–>32)
    imipenem:  S(MIC50): 0.03, MIC90: 0.25, RNG: (0.015-4)
    meropenem:  Var(MIC50): 1, MIC90: 16, RNG: (0.125–>32)
    azithromycin:  Var(MIC50): >2, MIC90: >128, RNG: (0.12->128)
    erythromycin:  S(MIC50): 1, MIC90: 8, RNG: (0.03->64)
    clarithromycin:  Var(MIC50): 0.25, MIC90: 4, RNG: (0.03->64)
    quin-dalf:  S(MIC50): 0.25, MIC90: 1, RNG: (0.06-2)
    roxithromycin:  Var(MIC50): 0.25, MIC90: 8, RNG: (0.03-16)
    telithromycin:  S(MIC50): 0.015, MIC90: 0.06, RNG: (0.015-0.06)
    josamycin:  R(MIC50): >16, MIC90: >64, RNG: (0.125->64)
    linezolid:  S(MIC50): 0.5, MIC90: 1, RNG: (0.125-1)
    levofloxacin:  S(MIC50): 1, MIC90: 4, RNG: (0.06-16)
    moxifloxacin:  S(MIC50): 0.25, MIC90: 0.25, RNG: (0.06–0.5)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.125–0.25)
    minocycline:  S(MIC50): 0.03, MIC90: 0.06, RNG: (0.03–0.125)
    tetracycline:  S(MIC50): 4, MIC90: 4, RNG: (0.125–4)
    teicoplanin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.25-0.5)
    vancomycin:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.25-0.5)
    rifapentine:  Var(MIC50): >0.015, MIC90: >128, RNG: (0.015->128)
    clindamycin:  R(MIC50): >32, MIC90: >32, RNG: (0.02->32)
    lincomycin:  Var(MIC50): >2, MIC90: >128, RNG: (0.5->128)
    daptomycin:  S(MIC50): 0.03, MIC90: 1, RNG: (0.03-8)

    References

    SPECIFIC REFERENCES FOR CORYNEBACTERIUM MINUTISSIMUM
  • Goldstein2003 - In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates.
  • Yassin2002 - Corynebacterium aurimucosum sp. nov. and emended description of Corynebacterium minutissimum Collins and Jones (1983).
  • Bernard2012Bergey - Bergey's manual of systematic bacteriology. Vol. 5, The Actinobacteria. Part A & B. Corynebacteriaceae, Genus I. Corynebacterium
  • Tyrrell2012 - In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.
  • Goldstein2008 - In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
  • Goldstein2000 - Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR CORYNEBACTERIUM MINUTISSIMUM
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • ...............................
    • GENERAL REFERENCES FOR CORYNEBACTERIUM MINUTISSIMUM
  • CCUG - Culture Collection University of Gothenburg - Entire Collection
    • Added: April 08, 2021